@ARTICLE{10.3389/fmicb.2021.790121, AUTHOR={Tariq, Hasnat and Batool, Sannia and Asif, Saaim and Ali, Mohammad and Abbasi, Bilal Haider}, TITLE={Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases}, JOURNAL={Frontiers in Microbiology}, VOLUME={12}, YEAR={2022}, URL={https://www.frontiersin.org/articles/10.3389/fmicb.2021.790121}, DOI={10.3389/fmicb.2021.790121}, ISSN={1664-302X}, ABSTRACT={Virus-like particles (VLPs) are nanostructures that possess diverse applications in therapeutics, immunization, and diagnostics. With the recent advancements in biomedical engineering technologies, commercially available VLP-based vaccines are being extensively used to combat infectious diseases, whereas many more are in different stages of development in clinical studies. Because of their desired characteristics in terms of efficacy, safety, and diversity, VLP-based approaches might become more recurrent in the years to come. However, some production and fabrication challenges must be addressed before VLP-based approaches can be widely used in therapeutics. This review offers insight into the recent VLP-based vaccines development, with an emphasis on their characteristics, expression systems, and potential applicability as ideal candidates to combat emerging virulent pathogens. Finally, the potential of VLP-based vaccine as viable and efficient immunizing agents to induce immunity against virulent infectious agents, including, SARS-CoV-2 and protein nanoparticle-based vaccines has been elaborated. Thus, VLP vaccines may serve as an effective alternative to conventional vaccine strategies in combating emerging infectious diseases.} }